Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis

  • End date
    Aug 31, 2023
  • participants needed
  • sponsor
    LintonPharm Co.,Ltd.
Updated on 16 May 2021
neutrophil count
liver metastasis
gastric cancer
gastric carcinoma
metastatic gastric cancer


A total of 297 subjects are estimated to enroll in the study, with 15 eligible subjects enrolled in the 1st stage at most and 282 evaluable subjects in the 2nd stage. All subjects are adult patients with age over 18-year-old; they must be diagnosed with recurrent or metastatic gastric cancer with peritoneal metastasis at the time of enrollment; and failed at least prior two standard systemic anti-cancer therapies for recurrent or metastatic gastric cancer, before enrollment.

In the first stage, pharmacokinetic characteristics and preliminary safety of catumaxomab will be explored in Asian patients with gastric cancer ; in Cohort A, the enrolled subjects will receive the first infusion at 10g on day 1, which will be increased to 20 g, 50 g and 150 g on days 4, 8 and 11, respectively. 42 days are defined as a cycle. From the second cycle, catumaxomab will be changed to 20 g, 50 g, 150 g on days 1, 4, 8 respectively. In Cohort B, 28 days are defined as a cycle. It is estimated to enroll 6 subjects in each cohort first.

In the second stage, approximate 282 subjects who meet the enrollment criteria are randomized into either catumaxomab infusion group (catumaxomab group) or treatment of investigator choice group (IC group), at a ratio of 2:1.

Subjects at the first and second stages will continue the treatment until one of the following conditions occurs:1)Significant progression of tumor lesions, including but not limited to peritoneal metastases lesions and/or ascites; 2)Intolerable toxicity; 3)The investigator believes that patients need to withdraw from the study and receive other treatment;4)death;5)Withdrawal of informed consent.

Condition Gastropathy, Stomach Discomfort, Gastric Cancer, Gastric Cancer, Stomach Cancer, Stomach Discomfort, Stomach Cancer, gastric neoplasm, gastric tumor
Treatment Catumaxomab, The treatment of investigator choice
Clinical Study IdentifierNCT04222114
SponsorLintonPharm Co.,Ltd.
Last Modified on16 May 2021


Yes No Not Sure

Inclusion Criteria

Signed and dated informed consent forms have been provided
Willing to be complaint with the study procedures during the study
Male or female, age18years old when signing informed consents
Histologically or cytologically confirmed as gastricadeno carcinoma
Evaluable and/or non-evaluable lesions according to RECISTV1.1 criteria
Diagnosed as gastric cancer with peritoneal metastases (Imaging finding, previous surgicalpathology, ascites/peritoneal effusion cytology positive)
Treatment failure after receiving at least prior two standard systemic anti-cancer therapies for recurrent or metastatic gastric cancer
Recovered from any toxicity due to previous treatment (Grade 0-1 according to NCI-CTCAEv5.0)
Estimated survival length3months
Eastern Oncology Cooperative Group(ECOG) performance status 0-2
The laboratory test values during the screening period are in accordance with the following tableANC(absolute neutrophil count) 1.5 10^9/L Hemoglobin 80 g/LPlatelet 100 10^9/L Lymphocyte percentage13%Serum Bilirubin 1.25 x ULN(or 2.5 x ULN if there is Gilbert) AST and ALT 2.5 ULN without liver metastasisor 5 ULN if liver metastasis Serum creatinine 2.0 mg/dL (or Calculated creatinine clearance30 mL/min)
For women of childbearing potential: use an efficient method for contraception at least 1 month prior to screening and agree to use this method for contraception during the study period and extended period specified after the study intervention
For men with fertility potential: use condoms or other methods to ensure effective contraception for sexual partners

Exclusion Criteria

Known or suspected of being allergic to catumaxomab or similar antibodies
Previously received anti-tumor treatments, including other anti-tumor investigational drugs, chemotherapy, immunotherapy, biological agents, hormone therapy, radiation therapy (except local radiation therapy for pain relief), etc., the interval between the last treatment and the first peritoneal infusion is 21days
There is extensive liver metastasis(the tumor volume is estimated to be50% of the total liver volume by imaging)
Known tumor in tra-cranial metastases
The following diseases have not been resolved to CTCAE grade 0-1 3 days before the first infusion
Uncontrolled acute and chronic infections such as pneumonia, biliary infection, hepatitis B virus infection and hepatitis C virus infection,etc
Acute or chronic pancreatitis
NYHA Class 3 or 4
Symptoms and signs of related cardiovascular diseases: including myocardial infarction, congestive heart failure,arrhythmia
Known cerebrovascular accidents
Intestinal obstruction occurred 30 days before the first dose
Imaging diagnosis of portal vein obstruction, including tumor compression or portal thrombosis,cancer thrombus
History of autoimmune diseases (e.g.,inflammatory bowel disease, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autologous hemolytic anemia, rheumatoid arthritis,etc.)
Patients with known HIV serology positive, hepatitis C infection and/or hepatitis B (Except the patients with HepBsAg or core antibody positive and responding to antiviral therapy against hepatitis B who are allowed to participate in the study; Notes: HepBsAg-negative patients at screening, or patients are undergoing treatment with interferon-2a [IFN] or peginterferon-2a [Peg-IFN] and hepatitis B virus [HBV] DNA < 2000 international units [IU], or subjects who are receiving nucleoside [acid] analogues at screening and HBV DNA below the lower limit of normal [LLN] are eligible to participate in the study)
Pregnancy or breast feeding during study treatment and follow-up
Patients with confirmed history of neurological or psychotic disorders, including epilepsy or dementia
Other serious systemic conditions that may limit the patient's participation in this study (eg uncontrolled diabetes, cardiovascular and cerebrovascular disease, severe gastrointestinal disease,etc.)
Any other condition that, in the discretion of the investigator will make patients exposed to unnecessary risks and unsuitable for participation in this clinical study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note